Recent research has shown that defects in DNA repair pathways can make tumors more susceptible to immunotherapy. Tumors with high mutation burdens, often due to defective DNA repair, produce more neoantigens that can be recognized by the immune system. This makes them more likely to respond to immune checkpoint inhibitors, which enhance the body's immune response against cancer cells.